Early prevention of dyslipidemia in children and adolescents as well as cardiovascular health in adulthood

XIANG Wei

doi:10.11852/zgetbjzz2023-0538

PDF(855 KB)

Chinese Journal of Child Health Care ›› 2023, Vol. 31 ›› Issue (7) : 697-702. DOI: 10.11852/zgetbjzz2023-0538

Expert Commentary

Early prevention of dyslipidemia in children and adolescents as well as cardiovascular health in adulthood

XIANG Wei

Author information +

History +

Abstract

In our country, cardiovascular disease (CVD) now ranks the first among independent risk factors for atherosclerosis(AS) and CVD, and it is now the leading cause of mortality in both urban and rural populations. Numerous studies have demonstrated that AS-related CVD begins with AS lesions in early childhood, and this process is correlated with increased plasma cholesterol levels. The prevalence of dyslipidemia among children and adolescents is increasing in China. The definition, latest categorization, diagnosis, and treatment of dyslipidemia in children and adolescents are presented in this article. Primary prevention places a focus on lifestyle prevention, genetic counseling, and avoiding harmful impacts of variables connected to the developmental genesis hypothesis of health and illness on fetuses and offspring. When it comes to secondary prevention, the focus is on the value of screening and the promotion of dyslipidemia screening in children at high/medium risk or with a positive family history. For children with moderate to severe dyslipidemia, tertiary prevention means careful dietary restriction and medication intervention. It is advised to refer patients to a multidisciplinary team of experts in tertiary prevention. Finally, the development of researches on adult cardiovascular health and early dyslipidemia prevention in children and adolescents is presented.

Key words

dyslipidemia / tertiary prevention / children

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

XIANG Wei. Early prevention of dyslipidemia in children and adolescents as well as cardiovascular health in adulthood[J]. Chinese Journal of Child Health Care. 2023, 31(7): 697-702 https://doi.org/10.11852/zgetbjzz2023-0538

References

[1] 中国血脂管理指南修订联合专家委员会.中国血脂管理指南(2023年)[J].中国循环杂志, 2023,38(3): 237-271.
Joint Committee on the Chinese Guidelines for Lipid Management.Chinese Guidelines for Lipid Management (2023)[J].Chinese Circulation Journal,2023,38(3):237-271.(in Chinese)
[2] Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart,Lung, and Blood Institute.Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Summary report[J]. Pediatrics,2011,128 (Suppl 5):213-256.
[3] 向伟,杜军宝.解读《儿童青少年血脂异常防治专家共识(2008)》[J].中华儿科杂志,2009,47(8):637-639
[4] 《中华儿科杂志》编辑委员会中华医学会儿科学分会儿童保健学组中华医学会儿科学分会心血管学组,等.儿童青少年血脂异常防治专家共识[J].中华儿科杂志,2009,47(6):426-428.
The Editorial Board of Chinese Journal of Pediatrics Null,the Subspecialty Group of Child Health Care, the Society of Pediatrics, Chinese Medical Association Null,et al.Experts consensus for prevention and treatment of dyslipidemia in children and adolescents[J]. Chin J Pediatr, 2009, 47(6): 426-428.(in Chinese)
[5] 程红, 肖培, 侯冬青, 等. 2017年北京市6～16岁儿童青少年血脂异常流行特征及相关因素[J]. 中国循环杂志,2020,35(6):566-572.
Cheng H,Xiao P,Hou DQ,et al.Epidemiological characteristics and related factors of dyslipidemia among Beijing children and adolescents aged 6-16 years in 2017[J]. Chinese Circulation Journal,2020,35(6):566-572.(in Chinese)
[6] He H, Pan L, Du J, et al. Prevalence of, and biochemical and anthropometric risk factors for, dyslipidemia in children and adolescents aged 7 to 18 years in China: A cross-sectional study[J]. Am J Hum Biol,2019,31(5):e23286.
[7] 王政和, 邹志勇, 阳益德, 等. 2012年中国7省份6～17岁儿童青少年血脂异常流行情况及相关因素分析[J].中华预防医学杂志,2018,52(8):798-801.
Wang ZH,Zou ZY,Yang YD,et al. The epidemiological characteristics and related factors of dyslipidemia among children and adolescents aged 6-17 years from 7 provinces in China, 2012[J].Chinese Journal of Preventive Medicine,2018,52(8):798-801.(in Chinese)
[8] 中华医学会心血管病学分会动脉粥样硬化及冠心病学组,中华心血管病杂志编辑委员会. 家族性高胆固醇血症筛查与诊治中国专家共识[J]. 中华心血管病杂志,2018,46(2):99-103.
Atherosclerosis and Coronary Heart Disease Group of the Chinese Society of Cardiology of Chinese Medical Association,Editorial Board of Chinese Journal of Cardiology.Chinese expert consensus on screening,diagnosis and treatment of familial hypercholesterolemia[J]. Chin J Cardiol, 2018,46(2): 99-103.(in Chinese)
[9] Bamba V. Update on screening, etiology, and treatment of dyslipidemia in children[J]. J Clin Endocrinol Metab,2014,99(9):3093-3102.
[10] Bibbins-Domingo K, Grossman DC, Curry SJ, et al.Screening for lipid disorders in children and adolescents: US preventive services task force recommendation statement[J]. JAMA, 2016,316(6):625-633.
[11] Vrablík M, Cˇesˇka R. Treatment of hypertriglyceridemia: a review of current options[J]. Physiol Res,2015,64(Suppl 3):331-340.
[12] Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemias:Recommendations from the national lipid association expert panel on familial hypercholesterolemia[J].J Clin Lipidol,2011,5(Suppl 3):30-37.
[13] Ramaswami U, Humphries SE, Priestley-Barnham L, et al. Current management of children and young people with heterozygous familial hypercholesterolaemia-HEART UK statement of care[J].Atherosclerosis,2019,290:1-8.
[14] King K, Macken A, Blake O, et al. Cholesterol screening and statin use in children:A literature review[J]. Ir J Med Sci,2019,188(1):179-188.
[15] Harada-Shiba M, Ohta T, Ohtake A, et al. Guidance for pediatric familial hypercholesterolemia 2017[J]. J Atheroscler Thromb,2018,25(6):539-553.
[16] Hajighasemi S, Mahdavi Gorabi A, Bianconi V, et al. A review of gene- and cell-based therapies for familial hypercholesterolemia[J].Pharmacol Res,2019,143:119-132.
[17] 向伟, 易著文,谢慧能, 等. 小儿肾脏疾病与脂质代谢紊乱[J].实用儿科临床杂志, 2008,23(5):381-384.
Xiang W, Yi ZW, Xie HN, et al.Renal disease in children and dyslipidoses[J]. J Appl Clin Pediatr, 2008, 23(5): 381-384.(in Chinese)
[18] 向伟.小儿血脂异常-基础与临床[M].北京:人民卫生出版社,2001年
[19] Akioyamen LE, Genest J, Shan SD, et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia:A systematic review and meta-analysis[J]. BMJ Open,2017,7(9):e016461.
[20] 黄丹, 邹朝春. 家族性高胆固醇血症的诊断和治疗进展[J].国际儿科学杂志,2018,45(5):389-392,396.
Huang D,Zou CC.Progress of diagnosis and treatment of familial hypercholesterolemia[J]. Int J Pediatr, 2018,45(5): 389-392,396.(in Chinese)
[21] 向伟,米杰.重视儿童青少年代谢综合征防治[J].中国儿童保健杂志杂志,2013,21(5):449-452.